However, a large subset of patients does not benefit from ICI therapy, with a reported objective response rate for anti-PD1 varying from almost absent (pancreatic cancer, glioma, microsatellite-stable colon adenocarcinoma) to 15–30% for most cancers, and 50–80% for few cancers including melanoma, Hodgkin lymphoma, squamous cell carcinoma and Merkel carcinoma (251). The gene discussed is PDCD1; the disease is cancer.